*J.P. Morgan Asia FTM 13 May 26 Hengrui’s record-setting $15.2bn global alliance; ASCO 2026 preview; D/g GENS to UW; IN Financials 4Q26 review; Sea Ltd: 1Q26 adj EBITDA beats; Kuaishou’s potential Kling AI plans

研报英文原文证据摘录

*J.P. Morgan Asia FTM 13 May 26 Hengrui’s record-setting $15.2bn global alliance; ASCO 2026 preview; D/g GENS to UW; IN Financials 4Q26 review; Sea Ltd: 1Q26 adj EBITDA beats; Kuaishou’s potential Kling AI plans

Asia Pacific Equity Research

This material is neither intended to be distributed to Mainland China investors nor to provide securities

investment consultancy services within the territory of Mainland China. This material or any portion hereof

may not be reprinted, sold or redistributed without the written consent of J.P. Morgan.

Asia First to Market 13 May 2026

Top Stories

Hengrui, China, Hong Kong (Yang Huang)

A record-setting US$15.2bn multi-asset global alliance, strengthening Hengrui’s shift from licensor

to strategic co-creator

Hengrui announced a global strategic collaboration and licensing agreement with Bristol-Myers Squibb

(BMS) yesterday (May 12), covering 13 early-stage projects spanning oncology, hematology, and

immunology, with a potential total transaction value of up to US$15.2bn. This represents Hengrui’s largest

BD transaction to date and is the second-largest China pharma out-licensing deal by total deal size —

behind only AstraZeneca’s US$18.5bn licensing agreement with CSPC signed earlier in 2026. The deal also

marks a meaningful strategic step-up from Hengrui’s prior landmark deal with GSK in 2025 (total deal size

up to ~US$12bn), which management described on yesterday’s investor call as the deal that validated the

Chinese pharma-MNC alliance model; the BMS transaction builds on that foundation by introducing Co-Co

optionality and joint early-stage discovery that the GSK deal did not include. We see the capital markets

reacted decisively: H-shares surged as much as 15% intraday before settling at approximately +4.8% on the